Obtaining Utility Estimates of the Health Value of Commonly Prescribed Treatments for Asthma and Depression

Maria Orlando Edelen, M. Audrey Burnam, Katherine E. Watkins, José J. Escarce, Haiden Huskamp, Howard H. Goldman and Gary Rachelefsky
Additional contact information
Maria Orlando Edelen: RAND Health, Santa Monica, California, Maria_Edelen@rand.org
M. Audrey Burnam: RAND Health, Santa Monica, California
Katherine E. Watkins: RAND Health, Santa Monica, California
José J. Escarce: RAND Health, Santa Monica, California
Haiden Huskamp: Harvard Medical School, Department of Health Care Policy, Cambridge, Massachusetts
Howard H. Goldman: Department of Psychiatry, University of Maryland School of Medicine, Baltimore
Gary Rachelefsky: Allergy Research Foundation, Inc., Los Angeles, California, Division of Allergy and Immunology, University of California, Los Angeles

Medical Decision Making, 2008, vol. 28, issue 5, 732-750

Abstract: Background. Comparing the costs and health value associated with alternative quality improvement efforts is useful. This study employs expert panel methodology to elicit numerical estimates based on a 0 to 1 utility scale of the health benefit of usual treatment patterns for 2 medical conditions. Method. The approach includes development of clinical profiles and derivation of treatment benefit estimates via the elicitation of utility ratings before and after treatment. Clinical profiles specified characteristics of patient groups, treatments to be rated, and their combinations. A panel of 13 asthma and depression experts made a series of utility ratings (before any new treatment, 1 or 3 mo later with no treatment, 1 or 3 mo after initiating various common treatments) for adult patient groups with depression or asthma. The panel convened to discuss discrepancies and subsequently made final ratings. Treatment benefit estimates were derived from the ratings made by the panelists after the panel meeting. Results. The treatment benefit estimates had face validity and minimal variability, indicating considerable consensus among experts. Treatment benefit estimates ranged from − 0.03 to 0.25 for depression and from − 0.04 to 0.24 for asthma. There was minimal variation in the estimates for both conditions (the estimates' standard deviations ranged from 0.01 to 0.06). Comparisons of the treatment benefit estimates before and after the expert panel meeting indicated substantial convergence, and evidence suggests that the benefit estimates are comparable across the 2 health conditions. Conclusion. Comparable estimates of treatment benefit for distinct health conditions can be obtained from experts using the expert panel methodology.

Keywords: Key words: expert panel; consensus panel; health value; treatment benefit; depression; asthma. (search for similar items in EconPapers)
Date: 2008
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X08315251 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:28:y:2008:i:5:p:732-750

DOI: 10.1177/0272989X08315251

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().